A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.

Trial Profile

A Phase 3, Randomized, Multicenter, Double-Blind, Allopurinol-Controlled Study Assessing the Efficacy and Safety of Oral Febuxostat in Subjects With Gout.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2013

At a glance

  • Drugs Febuxostat (Primary) ; Allopurinol
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms CONFIRMS
  • Most Recent Events

    • 28 May 2011 Results according to baseline comorbidities in diabetic patients were presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 18 Oct 2009 Additional data presented at the 73rd Annual Scientific Meeting of the American College of Rheumatology, according to a Protreolix media release.
    • 10 Nov 2008 Results were presented at the American College of Rheumatology meeting in Oct 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top